Talphera signals study completion in first half of 2026 as new site activations delay NEPHRO timeline [Seeking Alpha]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Seeking Alpha
Vincent Angotti, CEO, highlighted the completion of a $17 million two-tranche financing, including a $5 million strategic minority investment from CorMedix, which grants CorMedix a 60-day exclusive negotiation period for a potential acquisition after NEPHRO study Quick Insights Activation delays pushed expected Niyad study completion to first half of 2026 and increased operational risks. Talphera had $21.3 million cash at Q3 end and reduced 2025 expense guidance to $14-15 million, citing sufficient capital through a planned Niyad PMA approval. Management is submitting expanded eligibility criteria to the FDA and working closely with sites to accelerate enrollment and site activation. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- Assessing CorMedix (CRMD): Is the Current Share Price Reflecting Its True Value? [Yahoo! Finance]Yahoo! Finance
- Cormedix Inc (CRMD) Q3 2025 Earnings Call Highlights: Record Financial Performance and ... [Yahoo! Finance]Yahoo! Finance
- Does the Recent 9.9% Pullback Make CorMedix a Bargain in 2025? [Yahoo! Finance]Yahoo! Finance
- Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025 [Yahoo! Finance]Yahoo! Finance
- H.C. Wainwright Raises the PT on ?CorMedix Inc. (CRMD), Keeps a Buy [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 12/4/25 - Form 4
- 12/1/25 - Form SCHEDULE
- 11/26/25 - Form 4
- CRMD's page on the SEC website